Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K.’s Midatech Develops Transbuccal Insulin Using Gold Nanoparticles

This article was originally published in The Pink Sheet Daily

Executive Summary

The biocompatible gold nanoparticle technology being developed by the U.K. biotech can be used to carry insulin quickly to its site of action, and is also being evaluated with GLP-1 agonists and oncologics.

You may also be interested in...



Nanomedicine: Will It Get Big?

Big drugmakers will be watching closely to see if second-generation nanomed companies can program small particles to pack big pharmaceutical effects. We profile four start-ups that hope to show that they can: Blend Biosciences, Kala Pharma, Qualiber Technologies, and Uroboros Technologies.

Orphazyme Raises Funds, Approaching Markets With Novel Niemann-Pick Therapy

Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.

Sarepta's DMD Gene Therapy: Durable Responses After Two Years

Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel